HUMAN STEM CELLS INSTITUTE |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 59.54 RUB | +1.43% |
|
-.--% | -.--% |
| 26/04 | Artgen Biotech PJSC Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Artgen Biotech PJSC Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
| Sales 2022 | 1.14B 12.17M 1.02B | Sales 2023 | 1.37B 14.65M 1.22B | Capitalization | 4.42B 47.3M 3.95B |
|---|---|---|---|---|---|
| Net income 2022 | 46M 492K 41.09M | Net income 2023 | 169M 1.81M 151M | EV / Sales 2022 | 4.3 x |
| Net Debt 2022 | 605M 6.47M 540M | Net Debt 2023 | 242M 2.59M 216M | EV / Sales 2023 | 3.41 x |
| P/E ratio 2022 |
112
x | P/E ratio 2023 |
32.7
x | Employees | - |
| Yield 2022 |
1.68% | Yield 2023 |
-
| Free-Float | 22.77% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.43% |
3 years
34.35
177.00
5 years
8.08177.00
10 years
7.60177.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 54 | 27/03/27 | |
| Director of Finance/CFO | - | - | |
| Chief Administrative Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Andrey Isaev
BRD | Director/Board Member | 53 | 28/07/28 |
| Director/Board Member | 65 | 05/04/05 | |
Sergey Kiselev
BRD | Director/Board Member | 66 | 28/07/28 |
Institut Stvolovykh Kletok Cheloveka PAO (Human Stem Cells Institute OJSC or HSCI OJSC) is a Russia-based company engaged in the research and development, as well as commercialization and marketing of proprietary products and services in the areas of cell-based and gene and post-genome technologies. The Company is engaged in such projects as: Gemabank, cord blood stem cells bank; Gemascreen medical genetic diagnostics and consulting services provided by the Company domestically with the aim of early detection, treatment or prevention of inherited diseases; SPRS-therapy service a set of personalized diagnostics and treatment procedures; SynBio, which focuses on development of new medicines. In addition, the Company is a producer of Neovasculgen, a gene-therapy drug. In February 2014, it opened a biotech complex in Kyiv.
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 47.99M | |
| -14.87% | 84.68B | |
| +14.59% | 81.12B | |
| +10.49% | 29.59B | |
| -10.15% | 16.73B | |
| -1.39% | 16.36B | |
| -31.58% | 11.77B | |
| +1.82% | 11.72B | |
| +31.94% | 11.71B | |
| -0.47% | 11.66B |
- Stock Market
- Equities
- ISKJ Stock
